391 related articles for article (PubMed ID: 17640760)
1. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures.
Lempinen M; Isoniemi H; Mäkisalo H; Nordin A; Halme L; Arola J; Höckerstedt K; Stenman UH
J Hepatol; 2007 Nov; 47(5):677-83. PubMed ID: 17640760
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma.
Li YG; Zhang N
Dig Liver Dis; 2009 Aug; 41(8):605-8. PubMed ID: 19168405
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis.
Boberg KM; Jebsen P; Clausen OP; Foss A; Aabakken L; Schrumpf E
J Hepatol; 2006 Oct; 45(4):568-74. PubMed ID: 16879890
[TBL] [Abstract][Full Text] [Related]
4. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture.
Scarlett CJ; Saxby AJ; Nielsen A; Bell C; Samra JS; Hugh T; Baxter RC; Smith RC
Hepatology; 2006 Sep; 44(3):658-66. PubMed ID: 16941699
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis of biliary strictures in conjunction with endoscopic retrograde cholangiopancreaticography, with special reference to patients with primary sclerosing cholangitis.
Lindberg B; Arnelo U; Bergquist A; Thörne A; Hjerpe A; Granqvist S; Hansson LO; Tribukait B; Persson B; Broomé U
Endoscopy; 2002 Nov; 34(11):909-16. PubMed ID: 12430077
[TBL] [Abstract][Full Text] [Related]
6. Biliary brush cytology and the detection of cholangiocarcinoma in primary sclerosing cholangitis: evaluation of specific cytomorphologic features and CA19-9 levels.
Furmanczyk PS; Grieco VS; Agoff SN
Am J Clin Pathol; 2005 Sep; 124(3):355-60. PubMed ID: 16191503
[TBL] [Abstract][Full Text] [Related]
7. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis.
Patel AH; Harnois DM; Klee GG; LaRusso NF; Gores GJ
Am J Gastroenterol; 2000 Jan; 95(1):204-7. PubMed ID: 10638584
[TBL] [Abstract][Full Text] [Related]
8. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
9. Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis.
Albiin N; Smith IC; Arnelo U; Lindberg B; Bergquist A; Dolenko B; Bryksina N; Bezabeh T
Acta Radiol; 2008 Oct; 49(8):855-62. PubMed ID: 18608012
[TBL] [Abstract][Full Text] [Related]
10. Screening and diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis.
Jesudian AB; Jacobson IM
Rev Gastroenterol Disord; 2009; 9(2):E41-7. PubMed ID: 19668124
[TBL] [Abstract][Full Text] [Related]
11. Is a raised CA 19-9 level diagnostic for a cholangiocarcinoma in patients with no history of sclerosing cholangitis ?
John AR; Haghighi KS; Taniere P; Esmat ME; Tan YM; Bramhall SR
Dig Surg; 2006; 23(5-6):319-24. PubMed ID: 17170527
[TBL] [Abstract][Full Text] [Related]
12. FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis.
Wannhoff A; Hov JR; Folseraas T; Rupp C; Friedrich K; Anmarkrud JA; Weiss KH; Sauer P; Schirmacher P; Boberg KM; Stremmel W; Karlsen TH; Gotthardt DN
J Hepatol; 2013 Dec; 59(6):1278-84. PubMed ID: 23958938
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic role of serum interleukin 6 and CA 19-9 in patients with cholangiocarcinoma.
Tangkijvanich P; Thong-ngam D; Theamboonlers A; Hanvivatvong O; Kullavanijaya P; Poovorawan Y
Hepatogastroenterology; 2004; 51(55):15-9. PubMed ID: 15011822
[TBL] [Abstract][Full Text] [Related]
14. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma.
Uenishi T; Yamazaki O; Tanaka H; Takemura S; Yamamoto T; Tanaka S; Nishiguchi S; Kubo S
Ann Surg Oncol; 2008 Feb; 15(2):583-9. PubMed ID: 17955299
[TBL] [Abstract][Full Text] [Related]
15. Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis.
Tischendorf JJ; Krüger M; Trautwein C; Duckstein N; Schneider A; Manns MP; Meier PN
Endoscopy; 2006 Jul; 38(7):665-9. PubMed ID: 16673310
[TBL] [Abstract][Full Text] [Related]
16. Accuracy of the preoperative determination of tumor markers in the differentiation of liver mass lesions in surgical patients.
Torzilli G; Makuuchi M; Ferrero A; Takayama T; Hui AM; Abe H; Inoue K; Nakahara K
Hepatogastroenterology; 2002; 49(45):740-5. PubMed ID: 12063982
[TBL] [Abstract][Full Text] [Related]
17. Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma.
Tao LY; Cai L; He XD; Liu W; Qu Q
Am Surg; 2010 Nov; 76(11):1210-3. PubMed ID: 21140686
[TBL] [Abstract][Full Text] [Related]
18. A new mucin antibody/enzyme-linked lectin-sandwich assay of serum MUC5AC mucin for the diagnosis of cholangiocarcinoma.
Bamrungphon W; Prempracha N; Bunchu N; Rangdaeng S; Sandhu T; Srisukho S; Boonla C; Wongkham S
Cancer Lett; 2007 Mar; 247(2):301-8. PubMed ID: 16793202
[TBL] [Abstract][Full Text] [Related]
19. The value of biliary fibronectin for diagnosis of cholangiocarcinoma.
Chen CY; Lin XZ; Tsao HC; Shiesh SC
Hepatogastroenterology; 2003; 50(52):924-7. PubMed ID: 12845951
[TBL] [Abstract][Full Text] [Related]
20. Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma.
Nakeeb A; Lipsett PA; Lillemoe KD; Fox-Talbot MK; Coleman J; Cameron JL; Pitt HA
Am J Surg; 1996 Jan; 171(1):147-52; discussion 152-3. PubMed ID: 8554130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
